Table 1.
A summary of the drugs used in this study and their inhibitory spectrum against the cellular kinome
| Name | Concentration used | Main kinase target | Reference |
|---|---|---|---|
| Cetuximab | 30 μM | EGFR (Epidermal Growth Factor Receptor) | [7] |
| Erlotinib | 1 μM | EGFR | [15] |
| Afatinib | 10 μM | EGFR / ErbB2/ ErbB4 | [15] |
| Sorafenib | 10 μM | B-RAF, C-RAF, PDGFR-A, PDGFR-B (Platelet-Derived Growth Factor Receptor) | [15] |
| VEGFR-2 (Vascular Endothelial Growth Factor-2) | |||
| Masitinib | 10 μM | KIT, PDGFR-A, PDGFR-B | [15] |
| Tivantinib | 10 μM | HGFR (Hepatocyte Growth Factor Receptor) | [16] |
| Ponatinib | 1 μM | FGFR1-4 (Fibroblast-Growth Factor Receptor), PDGFR-A, VEGFR-2 | [17] |
| Rapamycin | 1 μM | mTOR (mammalian Target Of Rapamycin) | [18] |